{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:59:41Z","timestamp":1777575581559,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40256-023-00576-7","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:31:00Z","timestamp":1679887860000},"page":"311-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-1461","authenticated-orcid":false,"given":"Salil V.","family":"Deo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"LaForest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Altarabsheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakov E.","family":"Elgudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Dunlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simerpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill P.","family":"Pell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"576_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013143.","journal-title":"Circulation"},{"key":"576_CR2","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"576_CR3","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, IMPROVE-IT Investigators, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"576_CR4","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41440-019-0308-5","volume":"42","author":"M Sakuma","year":"2019","unstructured":"Sakuma M, Toyoda S, Hashimoto R, Yazawa H, Masuyama T, Hirose S, et al. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. Hypertens Res. 2019;42:1923\u201331.","journal-title":"Hypertens Res"},{"key":"576_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, FOURIER Steering Committee and Investigators, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"576_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, ODYSSEY OUTCOMES Committees and Investigators, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"576_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011246","volume":"8","author":"AM Chamberlain","year":"2019","unstructured":"Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, et al. PCSK9 inhibitor use in the real world: data from the national patient-centered research network. J Am Heart Assoc. 2019;8: e011246.","journal-title":"J Am Heart Assoc"},{"key":"576_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007237","volume":"14","author":"DM Blumenthal","year":"2021","unstructured":"Blumenthal DM, Maddox TM, Aragam K, Sacks CA, Virani SS, Wasfy JH. Predictors of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2021;14: e007237.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"576_CR9","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1161\/CIRCULATIONAHA.117.028430","volume":"136","author":"GP Hess","year":"2017","unstructured":"Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017;136:2210\u20139.","journal-title":"Circulation"},{"key":"576_CR10","unstructured":"Veterans Healthcare Administration. Veterans Healthcare Administration, 28 September 2021."},{"key":"576_CR11","unstructured":"Veterans Healthcare Administration. VA priority groups. Veterans Healthcare Administration; 2021."},{"key":"576_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019254","volume":"10","author":"CG Derington","year":"2021","unstructured":"Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, et al. Factors associated with PCSK9 inhibitor initiation among US veterans. J Am Heart Assoc. 2021;10: e019254.","journal-title":"J Am Heart Assoc"},{"key":"576_CR13","unstructured":"US Federal Poverty Guidelines Used To Determine Financial Eligibility For Certain Federal Programs. 18 January 2018."},{"key":"576_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024540","volume":"10","author":"CP Huded","year":"2021","unstructured":"Huded CP, Dalton JE, Kumar A, Krieger NI, Kassis N, Phelan M, et al. Relationship of neighborhood deprivation and outcomes of a comprehensive ST-segment-elevation myocardial infarction protocol. J Am Heart Assoc. 2021;10: e024540.","journal-title":"J Am Heart Assoc"},{"key":"576_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024057","volume":"11","author":"L Mathews","year":"2022","unstructured":"Mathews L, Ding N, Mok Y, Shin JI, Crews DC, Rosamond WD, et al. Impact of socioeconomic status on mortality and readmission in patients with heart failure with reduced ejection fraction: the ARIC Study. J Am Heart Assoc. 2022;11: e024057.","journal-title":"J Am Heart Assoc"},{"key":"576_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.annepidem.2018.11.008","volume":"30","author":"C Brokamp","year":"2019","unstructured":"Brokamp C, Beck AF, Goyal NK, Ryan P, Greenberg JM, Hall ES. Material community deprivation and hospital utilization during the first year of life: an urban population-based cohort study. Ann Epidemiol. 2019;30:37\u201343.","journal-title":"Ann Epidemiol"},{"key":"576_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228\u201334.","journal-title":"Commun Stat Simul Comput"},{"key":"576_CR18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.gaceta.2008.12.001","volume":"23","author":"JP Vandenbroucke","year":"2009","unstructured":"Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Gac Sanit. 2009;23:158.","journal-title":"Gac Sanit"},{"key":"576_CR19","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","volume":"69","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:e71\u2013126.","journal-title":"J Am Coll Cardiol"},{"key":"576_CR20","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:2160\u2013236.","journal-title":"Stroke"},{"key":"576_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338\u201350.","journal-title":"Circulation"},{"key":"576_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","volume":"51","author":"RP Giugliano","year":"2020","unstructured":"Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020;51:1546\u201354.","journal-title":"Stroke"},{"key":"576_CR23","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.jacc.2021.04.060","volume":"77","author":"CN Hess","year":"2021","unstructured":"Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, et al. Effectiveness of blood lipid management in patients with peripheral artery disease. J Am Coll Cardiol. 2021;77:3016\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"576_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005910","volume":"12","author":"K Nasir","year":"2019","unstructured":"Nasir K, Angraal S, Virani SS. PCSK9 Inhibitors Prior Authorization. Circ Cardiovasc Qual Outcomes. 2019;12: e005910.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"576_CR25","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.clinthera.2007.12.022","volume":"29","author":"X Ye","year":"2007","unstructured":"Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29:2748\u201357.","journal-title":"Clin Ther"},{"key":"576_CR26","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.37765\/ajmc.2020.43493","volume":"26","author":"X Yuan","year":"2020","unstructured":"Yuan X, Chaisson J, Cantrell D, Mohundro BL, Carby M, Ford M, et al. Value-based insurance design in Louisiana: blue cross blue shield\u2019s zero dollar Co-pay program. Am J Manag Care. 2020;26:e179\u201383.","journal-title":"Am J Manag Care"},{"key":"576_CR27","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/ejhf.2378","volume":"23","author":"PM Seferovic","year":"2021","unstructured":"Seferovic PM, Polovina M, Adlbrecht C, Belohlavek J, Chioncel O, Goncalvesova E, et al. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23:1999\u20132007.","journal-title":"Eur J Heart Fail"},{"key":"576_CR28","first-page":"63","volume":"25","author":"B Briesacher","year":"2003","unstructured":"Briesacher B, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ Rev. 2003;25:63\u201376.","journal-title":"Health Care Financ Rev"},{"key":"576_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012\u201322.","journal-title":"Eur Heart J"},{"key":"576_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/VHRM.S180496","volume":"14","author":"DM Hines","year":"2018","unstructured":"Hines DM, Rane P, Patel J, Harrison DJ, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409\u201318.","journal-title":"Vasc Health Risk Manag."},{"key":"576_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jcpt.13271","volume":"46","author":"J Lee","year":"2021","unstructured":"Lee J, Lee SH, Kim H, Lee SH, Cho JH, Lee H, et al. Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin\/ezetimibe combination therapy: real-world evidence. J Clin Pharm Ther. 2021;46:134\u201342.","journal-title":"J Clin Pharm Ther"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00576-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00576-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00576-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T09:26:50Z","timestamp":1683365210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00576-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00576-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"22 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Naveed Sattar receives research grants from Amgen, AstraZeneca, and Boehringer Ingelheim. Salil V. Deo, David McAllister, Sharon LaForest, Salah Altarabsheh, Yakov E. Elgudin, Shannon Dunlay, Simerpreet Singh, Sahil Parikh, and Jill P. Pell have no potential conflicts of interest that might be relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"SVD: Conceptualization, data collection, statistical analysis, and drafting and revising the manuscript. DMA: Supervision, and reviewing and editing the manuscript. SLF: Drafting the manuscript. SA: Editing the manuscript. YEE: Revising the manuscript. SD: Revising the manuscript. SS: Writing the manuscript. SP: Revising the manuscript. NS: Supervision, conceptualization, and revising the manuscript. JPP: Conceptualization, revising the manuscript, and supervision.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was approved by the Research and Development Committee of the Louis Stokes Cleveland VA Medical Center (approval no. 019-045).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data used in this study cannot be shared as it is the property of the Department of Veteran Affairs. Investigators credentialled to conduct research by the Department of Veteran Affairs can obtain data using the standard channels. Code used in the statistical analyses conducted for this study can be obtained from the corresponding author on reasonable request or downloaded at: .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":".","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}